Episodes
![Highlights in colorectal cancer at ASCO GI 2024](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Mar 08, 2024
Highlights in colorectal cancer at ASCO GI 2024
Friday Mar 08, 2024
Friday Mar 08, 2024
In this week's podcast by VJ Oncology, six leading experts share their insights on cutting-edge developments in colorectal cancer screening and treatment, drawn from highlights of the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. One key focus was the rapid evolution of non-invasive blood-based tests for colorectal cancer screening, as discussed by Aasma Shauka from New York University. Further, Theodore R. Levin from Kaiser Permanente shared the effectiveness of stool-based testing in achieving high adherence rates for colorectal cancer screening. Meanwhile, Sebastian Stintzing from Charité – Universitätsmedizin Berlin analyzed the Phase II FRASCO2 trial, demonstrating the benefit of fruquintinib for heavily pre-treated patients with refractory metastatic colorectal cancer in a Q-TWIST analysis. Edward Esplin from Invitae speaks on the potential of personalized monitoring tests in early-stage colorectal cancer treatment and Van K. Morris from the University of Texas analyzing a prospective phase 2 clinical trial for previously treated metastatic colorectal cancer. Finally, Anwar Saeed's discusses the rationale behind STELLAR-303 trial aiming to address unmet needs of patients with specific types of metastatic colorectal cancer.
![Targeted therapies for lung cancer at TTLC 2024](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Mar 01, 2024
Targeted therapies for lung cancer at TTLC 2024
Friday Mar 01, 2024
Friday Mar 01, 2024
This week, we cover interesting research from TTLC 2024, focusing on innovative treatments for lung cancer. Starting off, Bruna Pellini from Moffitt Cancer Center, FL, talks about the utility of circulating tumor DNA as a biomarker of progression in lung cancer, her latest findings from notable Phase III trials and ongoing studies looking into increasing treatment based on this biomarker.
Next, Monica Chen from Memorial Sloan Kettering Cancer Center, NY, discusses the role of osimertinib with chemotherapy as initial treatment for patients with metastatic EGFR mutant lung cancers with concurrent TP53 and RB1 alterations from a clinical trial perspective.
Our final speaker, Timothy Burns from University of Pittsburgh, PA, shares detailed insights into non-TKI treatment options for EGFR mutant lung cancer. He discusses the exciting prospects of upcoming studies, potential FDA approvals and the integrated role of immuno-modulatory agents in EGFR mutant patients.
Our podcast aims to deliver the latest and most intriguing updates in the field directly to you. Follow us on Twitter at @vjoncology and visit our website for the newest trends.
![Updates in invasive lobular carcinoma (ILC)](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Feb 23, 2024
Updates in invasive lobular carcinoma (ILC)
Friday Feb 23, 2024
Friday Feb 23, 2024
Invasive lobular carcinoma (ILC) poses unique challenges in breast cancer management. Its subtle presentation and distinct biological behavior demand a nuanced approach from healthcare professionals. In this podcast, we delve into the epidemiology, pathology, diagnostic methods, treatment modalities, and emerging research surrounding ILC. By comprehensively understanding this subtype, healthcare professionals can optimize patient care and ultimately improve patient outcomes. In this enlightening podcast from VJ Oncology, join our distinguished guests, Jason Aboudi Mouabbi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Fresia Pareja, MD, Memorial Sloan Kettering Cancer Center, New York, NY, as they delve into the complexities of ILC.
![Esophageal and gastric cancer highlights from ASCO GI 2024](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Feb 16, 2024
Esophageal and gastric cancer highlights from ASCO GI 2024
Friday Feb 16, 2024
Friday Feb 16, 2024
In this podcast, we will discuss key insights from the 2024 ASCO Gastrointestinal (GI) Cancers Symposium held in San Francisco, CA. Topics include updates in the KEYNOTE-811, MATTERHORN, and CheckMate 649 trials, as well as the use of circulating free DNA analysis in esophagogastric cancer and the evolving landscape of treatment of HER2-positve metastatic gastric cancer. Additionally, hear on a pilot PET study using the positron-emitting agent 18F-BMS-986229 for PD-L1 imaging in advanced esophagogastric cancer and a retrospective investigation into the concordance between three PD-L1 scoring methods and their association with clinical outcomes in RATIONALE-302.
Tune in to hear perspectives from experts such as Yelena Y. Janjigian (Memorial Sloan Kettering Cancer Center, New York, NY), Samuel Louis Cytryn (Memorial Sloan Kettering Cancer Center, New York, NY), Kohei Shitara (National Cancer Center Hospital East, Kashiwa, Japan), Ken Kato (National Cancer Center Hospital, Tokyo, Japan) and Nataliya V. Uboha (University of Wisconsin Carbone Cancer Center, Madison, WI).
![Key updates at ASCO GU 2024](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Feb 09, 2024
Key updates at ASCO GU 2024
Friday Feb 09, 2024
Friday Feb 09, 2024
In this podcast, we will discuss key insights from the 2024 ASCO Genitourinary (GU) Cancers Symposium held in San Francisco, CA. Topics include updates in the AMBASSADOR, CONTACT-2, and CLEAR trials, as well as why BCG-unresponsive patients with non-muscle invasive bladder cancer refuse cystectomy and the emerging role transperineal prostate biopsies. Tune in to hear perspectives from experts such as Andrea Apolo (National Institutes of Health, Bethesda, MD), Kim Chi (BC Cancer Vancouver Centre, Vancouver, Canada), Viktor Grünwald (University Hospital Essen, Essen, Germany), Joseph Jacob (Upstate Medical University, Syracuse, NY), and Jim Hu (Weill Cornell Medicine, New York, NY).
![Highlights in bladder and prostate cancer at PROCSA/BLADDR 2023](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Feb 02, 2024
Highlights in bladder and prostate cancer at PROCSA/BLADDR 2023
Friday Feb 02, 2024
Friday Feb 02, 2024
In this podcast, we’ll be covering highlights from the PROCSA/BLADDR 2023 Meeting, which took place in Valencia, Spain, such as the evolution of targeted therapies and novel biomarker driven studies in prostate cancer, as well as trimodal therapy for non-muscle invasive bladder cancer. Hear from Rob Jones (The University of Glasgow, Glasgow, UK), Bertrand Tombal (Université catholique de Louvain, Ottignies-Louvain-la-Neuve, Belgium), Daniele Raggi (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Bram De Laere (Ghent University, Ghent, Belgium), Paul Sargos (Institut Bergonié, Bordeaux, France), Felix Guerrero-Ramos (Hospital Universitario 12 de Octubre, Madrid, Spain), Eva Compérat (Medical University of Vienna, Vienna, Austria).
![Key updates at ESMO Asia 2023](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Jan 26, 2024
Key updates at ESMO Asia 2023
Friday Jan 26, 2024
Friday Jan 26, 2024
The recent European Society for Medical Oncology (ESMO) Asia 2023 Congress in Singapore, brought together key oncology experts to delve into the latest oncology advancements. In this podcast episode, we are honored to host discussions with distinguished guests: Enrique Grande (MD Anderson Cancer Centre Madrid, Madrid, Spain), Molly Li (Queen Elizabeth Hospital, Hong Kong), Karijn Suijkerbuijk (UMC Utrecht, Utrecht, The Netherlands), and Hidehito Horinouchi (National Cancer Center Hospital, Tokyo, Japan).
The conversation will provide insights into noteworthy perspectives on cellular therapy development in Asia, the use of immunotherapies for advanced acral and mucosal melanoma, novel ADCs in EGFR-mutant lung cancer and a potential new standard of care in urothelial cancer.
![Breast Cancer Sessions: Highlights from SABCS 2023 with Sara Tolaney, Sarah Sammons & Paolo Tarantino](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Jan 12, 2024
Friday Jan 12, 2024
The San Antonio Breast Cancer Symposium (SABCS) 2023 took place on the 5-9th of December 2023 in San Antonio, TX. Leading experts in breast cancer came together to hear the latest clinical trial data and discuss how to improve care for patients with breast cancer.
In this podcast, we hear from Sara Tolaney, MD, MPH, Sarah Sammons, MD, and Paolo Tarantino, MD, of Dana-Farber Cancer Institute, Boston, MA, as they discuss the hot topics from SABCS 2023 in an exclusive roundtable discussion. Topics covered include updates on the management of HR+/HER2- breast cancer such as the role of CDK4/6 inhibitors as evaluated in MONARCH 3 (NCT02246621) and PARSIFAL (NCT02491983), the potential of PIK3CA described in the INAVO120 trial (NCT04191499), the use of ribociclib and endocrine therapy as adjuvant treatment in HR+/HER2- early breast cancer, and finally neoadjuvant immunotherapy in HR-positive early breast cancer.
![Updates in GI cancer at ESMO 2023](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Jan 05, 2024
Updates in GI cancer at ESMO 2023
Friday Jan 05, 2024
Friday Jan 05, 2024
The European Society for Medical Oncology (ESMO) Congress 2023 brought together leading experts to explore and deliberate on the most recent advancements and breakthroughs in the field of oncology. In this podcast, joining us will be John H. Strickler (Duke Cancer Institute, Durham, NC), Stephen L. Chan (The Chinese University of Hong Kong, Hong Kong, China), Benedikt Westphalen (Ludwig-Maximilians-University (LMU) Hospital, Munich, Germany), Filippo Pietrantonio (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy), Yoshiaki Nakamura (National Cancer Center Hospital East, Kashiwa, Japan) and Lorenza Rimassa (Humanitas University, Milan, Italy).
Discussions cover updates from various trials, emphasizing the effectiveness of tucatinib plus trastuzumab in HER2-positive RAS-WT metastatic colorectal cancer (mCRC) in the MOUNTAINEER (NCT03043313) trial and sotorasib with panitumumab in KRAS G12C mCRC in the CodeBreak 300 trial. Trials in hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) trials are highlighted and data on ctDNA as a prognostic biomarker in resected CRC is discussed, as well as prognostic factors contributing to long-term survivorship in patients with hepatobiliary cancers and advances in targeting KRAS in GI malignancies.
![2023 updates in metastatic colorectal cancer genomic biomarkers](https://pbcdn1.podbean.com/imglogo/image-logo/9722812/vj-onc-pod-tile_300x300.png)
Friday Dec 22, 2023
2023 updates in metastatic colorectal cancer genomic biomarkers
Friday Dec 22, 2023
Friday Dec 22, 2023
Huge advancements in personalized medicine and the availability of genetic testing have led us to consider the use of genomic alterations as biomarkers in cancer treatment. In this podcast, we will revisit the most recent developments in the efficacy and clinical application of genomic biomarkers in metastatic colorectal cancer (mCRC) presented during 2023.
We will hear from Filippo Pietrantonio, MD, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy, regarding the CodeBreak 300 trial (NCT05198934); John H. Strickler, MD, Duke Cancer Institute, Durham, NC, on MOUNTAINEER (NCT03043313); Ardaman Shergill, MD University of Chicago, Chicago, IL, on PARADIGM (NCT02394795), STRATEGIC-1 (NCT01910610) and CAIRO5 (NCT02162563) and Benny Johnson, DO, The University of Texas MD Anderson Cancer Center, Houston, TX, who rounds off the discussion by considering the use of circulating tumor DNA (ctDNA) to assess minimal residual disease (MRD) status.
Be sure to visit our dedicated page on genomic biomarkers in metastatic colorectal cancer here to learn more about current and future biomarker testing standards, as well as potential treatment directions in the future.